An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
Part of paid clinical trials in Orange, California.
- Sponsor
- Janssen Research & Development, LLC
- Study ID
- NCT00488774
- Phase
- PHASE2/PHASE3
- Status
- Terminated
Conditions
- Colitis, Ulcerative
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Placebo — OTHERMatching placebo for golimumab, intravenous infusion administered at Week 0
- Golimumab 1 mg per kg — DRUGGolimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
- Golimumab 2 mg per kg — DRUGGolimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
- Golimumab 4 mg per kg — DRUGGolimumab 4 mg per kg intravenous (IV) infusion at Week 0
Study Details
The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with active ulcerative colitis (UC) (sores in the colon).
Key Dates
- Start date
- Aug 31, 2007
- Status verified
- Apr 2013
- Primary completion
- May 31, 2009
- Completion
- May 31, 2009
Study Design
- Enrollment
- 291 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: PlaceboMatching placebo for golimumab, intravenous (IV) (through a vein in the arm) infusion administered at Week 0
- Experimental: Golimumab 1 milligram (mg) per kilogram (kg)Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0.
- Experimental: Golimumab 2 mg per kgGolimumab 2 mg per kg intravenous (IV) infusion administered at Week 0.
- Experimental: Golimumab 4 mg per kgGolimumab 4 mg per kg, intravenous (IV) infusion administered at Week 0.
Primary Outcome Measure
Number of Participants With Clinical Response [ Time Frame: Week 6 ]
Locations (36)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Orange | California | - | - |
| - | Roseville | California | - | - |
| - | Littleton | Colorado | - | - |
| - | Bristol | Connecticut | - | - |
| - | Tampa | Florida | - | - |
| - | Fort Dodge | Iowa | - | - |
| - | Topeka | Kansas | - | - |
| - | Louisville | Kentucky | - | - |
| - | Laurel | Maryland | - | - |
| - | Dearborn | Michigan | - | - |
| - | Troy | Michigan | - | - |
| - | Mexico | Missouri | - | - |
| - | St Louis | Missouri | - | - |
| - | Lebanon | New Hampshire | - | - |
| - | Great Neck | New York | - | - |
| - | Huntington | New York | - | - |
| - | New York | New York | - | - |
| - | Charlotte | North Carolina | - | - |
| - | Kinston | North Carolina | - | - |
| - | Cincinnati | Ohio | - | - |
| - | Cleveland | Ohio | - | - |
| - | Oklahoma City | Oklahoma | - | - |
| - | Tulsa | Oklahoma | - | - |
| - | Philadelphia | Pennsylvania | - | - |
| - | Charleston | South Carolina | - | - |
| - | Columbia | South Carolina | - | - |
| - | Germantown | Tennessee | - | - |
| - | Nashville | Tennessee | - | - |
| - | Austin | Texas | - | - |
| - | Galveston | Texas | - | - |
| - | Burlington | Vermont | - | - |
| - | Christiansburg | Virginia | - | - |
| - | Richmond | Virginia | - | - |
| - | Bellevue | Washington | - | - |
| - | Madison | Wisconsin | - | - |
| - | Milwaukee | Wisconsin | - | - |
Related Studies
- A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative ColitisRecruiting · Janssen Scientific Affairs, LLC · Portsmouth, Virginia
- Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese PatientsPHASE2 · Recruiting · University of California, San Diego · La Jolla, California
- A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative ColitisPHASE2/PHASE3 · Recruiting · Bristol-Myers Squibb · Phoenix, Arizona
- An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative ColitisRecruiting · Pfizer · Mesa, Arizona